Case Study
Monday, October 07
12:00 PM - 12:30 PM
Live in Berlin
Less Details
Biosimilars are still a somewhat new market where the regulatory framework is still being shaped. Successful market access for us requires a comprehensive approach integrating regulatory, clinical, economic, and commercial considerations to be able to maximize the adoption of biosimilars. How do we do it and how is the HTA regulation changing things for us?
In this presentation you will learn: